ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK–(Company WIRE)–#Action–Bragar Eagel & Squire, P.C., a nationally acknowledged shareholder legal rights regulation agency, is investigating probable statements in opposition to Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of lengthy-time period stockholders pursuing a class motion complaint that was submitted towards Athira on June 25, 2021 with a Course Period of time from September 17, 2020 to June 17, 2021. Our investigation fears whether or not the board of directors of Athira have breached their fiduciary responsibilities to the company.

On June 17, 2021, after the market closed, Athira declared that it experienced positioned its president and Chief Government Officer, Dr. Leen Kawas (“Kawas”), on go away pending a evaluation of actions stemming from doctoral exploration she conducted although at Washington Point out College (“WSU”).

The same day, STAT released an posting stating that WSU was investigating statements that Dr. Kawas “published many papers containing altered illustrations or photos while she was a graduate pupil.” These papers “are foundational to Athira’s attempts to address Alzheimer’s” due to the fact they “established that a individual molecule affects the activity of HGF.” Though Athira is acquiring a distinct molecule than the a person Kawas examined in the papers at concern, her “doctoral do the job laid the biological groundwork that Athira carries on to use in their solution to managing Alzheimer’s.”

The Registration Assertion was materially untrue and deceptive and omitted to condition: (1) that Kawas had revealed study papers made up of improperly altered photos even though she was a graduate university student (2) that this purported exploration was foundational to Athira’s attempts to produce treatments for Alzheimer’s simply because it laid the organic groundwork that Athira was utilizing in its approach to dealing with Alzheimer’s (3) that, as a final result, Athira’s intellectual residence and item enhancement for the remedy of Alzheimer’s ended up primarily based on invalid investigation and (4) that, as a result of the foregoing, Defendants’ beneficial statements about the Company’s company, functions, and prospective customers, ended up materially deceptive and/or lacked a affordable basis.

If you are a very long-time period stockholder of Athira, have information, would like to study much more about these claims, or have any thoughts concerning this announcement or your rights or pursuits with respect to these matters, make sure you contact Brandon Walker or Alexandra B. Raymond by email at [email protected], or telephone at (212) 355-4648, or by filling out this get hold of variety. There is no charge or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law agency with workplaces in New York and California. The company represents person and institutional investors in commercial, securities, spinoff, and other complicated litigation in condition and federal courts across the region. For much more data about the company, you should pay a visit to www.bespc.com. Attorney promotion. Prior success do not assure equivalent outcomes.

Contacts

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Alexandra B. Raymond, Esq.

(212) 355-4648

[email protected]
www.bespc.com